Plasticell, the biotechnology company specialising in cell and gene therapy research, has completed an equity financing round raising a total of £1.4 million.
Plasticell specialises in using massively parallel screening technologies to discover, develop and optimise manufacturing of high value cell therapies derived from stem cells. Its award-winning combinatorial screening technology, CombiCult®, can be applied to any cell culture process including biopharmaceutical production, as well as cell and gene therapy manufacturing.
Plasticell’s lead therapeutic programme is in the expansion of hematopoietic stem cells derived from bone marrow and cord blood, for both cell and gene therapy applications. The company has previously announced securing government grants of over £2 million to develop GMP manufacturing and complete pre-clinical work streams for this therapy.
In addition to advancing this therapy towards the clinic, the financing will be deployed to progress earlier-stage programmes in allogeneic immunotherapies.